Torrent Pharma’s profit rises 14% to ₹503 cr in Q3

Driven by strong growth in its India business, Ahmedabad-based Torrent Pharmaceuticals reported a 14 per cent year-on-year growth in profit after tax (PAT) for the third quarter of the financial year 2024-25.

While the company’s consolidated profits rose to ₹503 crore for the third quarter, its net sales grew by 2.6 per cent to ₹2,762 crore, for the same period. While the revenues from its India business grew 12 per cent for the third quarter, the revenues from Brazil and the US, fell by seven per cent and one per cent, respectively. Revenue from Germany rose by 4 per cent for the third quarter.

Torrent Pharmaceuticals, the flagship company of the Torrent Group, also announced an interim dividend of ₹26 per share for the quarter.